Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autoimmune Conditions Clear all
Terminated Phase 2 Interventional

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

NCT05785819
View directory record Official record
Conditions
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Interventions
VLX-1005, Placebo
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 14, 2026, 2:57 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Ultraviolet Light Therapy for Systemic Lupus Erythematosus

NCT00004375
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ultraviolet A-1 light treatment
Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
15 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1991
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 14, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CT-868, Placebo, Victoza
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 14, 2026, 2:57 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Obesity and Pediatric Multiple Sclerosis

NCT04593082
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 20 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Terminated Phase 2 Interventional

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

NCT01636817
View directory record Official record
Conditions
Inflammation, Rheumatoid Arthritis
Interventions
NNC0109-0012, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
92
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 14, 2026, 2:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 14, 2026, 2:57 AM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

NCT01359826
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Widespread Pain, Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 14, 2026, 2:57 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Completed No phase listed Observational

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

NCT01974232
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Months to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 14, 2026, 2:57 AM EDT
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Withdrawn Not applicable Interventional

Reducing Problematic Substance Use in Youth With Chronic Medical Conditions

NCT01709201
View directory record Official record
Conditions
Alcohol Abuse, Drug Abuse
Interventions
Brief Intervention
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 14, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis

NCT00432900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[(11)C]PBR28
Radiation
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 14, 2026, 2:57 AM EDT
Recruiting Not applicable Interventional

Healthier: Health Coaching for People With Rheumatoid Arthritis to Improve Mental Well-Being

NCT07222696
View directory record Official record
Conditions
Rheumatoid Arthritis (RA
Interventions
Peer Coach, Healthy Horizons
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Terminated Phase 3 Interventional

Autoimmunity in Inner Ear Disease

NCT00000361
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Corticosteroids, Methotrexate
Drug
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2006 · Synced Sep 14, 2026, 2:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

NCT04657094
View directory record Official record
Conditions
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Acalabrutinib
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Regulation of Mucosal Healing in Inflammatory Bowel Disease

NCT04504136
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Serial Biopsy
Procedure
Lead sponsor
Terrence A Barrett
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 14, 2026, 2:57 AM EDT
Completed Not applicable Interventional

Day and Night Closed-loop in Young People With Type 1 Diabetes

NCT02925299
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM (US) and FlorenceX (UK), Insulin pump therapy
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 18 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Hartford, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 14, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

NCT01600716
View directory record Official record
Conditions
Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
Interventions
OnabotulinumtoxinA, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 14, 2026, 2:57 AM EDT
Completed Phase 2Phase 3 Interventional

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334
View directory record Official record
Conditions
Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
Interventions
NC-503 (Anti-amyloidotic (AA) Agent)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2006 · Synced Sep 14, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 14, 2026, 2:57 AM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Recruiting Phase 3 Interventional

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

NCT07067463
View directory record Official record
Conditions
Multiple Sclerosis (MS) Primary Progressive
Interventions
Orelabrutinib, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Pheonix, Arizona • Scottsdale, Arizona • West Hollywood, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 14, 2026, 2:57 AM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 14, 2026, 2:57 AM EDT